- Home
- ARAY vs MRSN Comparison
ARAY vs MRSN Comparison
Compare ARAY & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARAY | MRSN |
|---|---|---|
| Founded | 1990 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.1M | 138.8M |
| IPO Year | 2007 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ARAY | MRSN |
|---|---|---|
| Price | $0.99 | $27.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.50 | ★ $30.38 |
| AVG Volume (30 Days) | ★ 1.2M | 237.3K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $450,902,000.00 | $33,180,000.00 |
| Revenue This Year | $3.82 | N/A |
| Revenue Next Year | $4.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.51 | N/A |
| 52 Week Low | $0.91 | $5.21 |
| 52 Week High | $2.95 | $70.73 |
Technical Indicators
Market Signals| Indicator | ARAY | MRSN |
|---|---|---|
| Relative Strength Index (RSI) | 32.66 | 84.04 |
| Support Level | $1.00 | $27.31 |
| Resistance Level | $1.06 | $28.36 |
| Average True Range (ATR) | 0.06 | 0.49 |
| MACD | 0.02 | -0.34 |
| Stochastic Oscillator | 34.85 | 68.18 |
Price Performance
Historical ComparisonAbout ARAY Accuray Incorporated
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.